About Us
About Novo Genomics
We are a Saudi Biotech company focused on localizing and applying technologies in genomics & multi-omics. We leverage advanced analytics and data mining to promote health and wellness across the Kingdom and the region.
- Leading genomics innovation in the Middle East
- Empowering precision medicine and preventive healthcare
- Partnering with academic, clinical, and research institutions
- Committed to Saudi Vision 2030 in biotech and health sectors
Why Novo Genomics?
Novo Genomics is a Saudi Biotechnology Company based in Riyadh, we believe that Genomics and Multi-omics will transform healthcare and wellness as we know it, not just for humans (Clinical & Personalized Medicine) but for animals and plants (Agri-genomics) as well. Our region has one of the highest prevalence (per capita) of genetic diseases worldwide. With a high-caliber core team, experienced advisors, and strategic investors, Novo Genomics has all the ingredients to be a serious player in the field of genomics / multi-omics in the region and beyond.
Our Vision
NOVO GENOMICS To be regionally trusted and globally recognized biotech leader in the field of genomics & multi-omics.has compiled the detailed information provided on this Website from internal and external sources to the best of its knowledge and belief, using professional diligence. We endeavor to expand and update this range of information continuously. The information on this Website is purely to present NOVO GENOMICS and its products and services. However, no representation is made or warranty given, either expressly or tacitly, for the completeness or correctness of this Website’s information. Please be aware that this information, although accurate on the day it was published, may no longer be up to date. Therefore, we recommend that you check any information you obtain from this Website before using it in any form. Advice given on this Website does not exempt you from conducting your own checks on our latest advice – particularly our safety data sheets and technical specifications – and on our products, with a view to their suitability for the intended processes and purposes. Should you require any advice or instructions concerning our products or services, please contact us directly. Users of this Website declare that they agree to access the Website and its content at their own risk. Neither NOVO GENOMICS nor third parties involved in the writing, production, or transmission of this Website can be held liable for damage or injury resulting from the access or the impossibility of access or from the use or impossibility of the use of this Website or from the fact that you have relied on information given on this Website.
Dr. Abdulelah Alhawsawi
At Novo Genomics, we are honored to stand at the forefront of precision medicine in Saudi Arabia and the broader Middle East. Our journey is guided by a singular vision: to harness the power of genomics, data science, and next-generation biotechnology to transform healthcare delivery, improve patient outcomes, and contribute to a knowledge-based, innovation-driven economy.
More Information
As a Saudi-founded biotechnology company, we are deeply committed to developing solutions that are scientifically rigorous, regionally relevant, and clinically impactful. Through investments in localized research, strategic international collaborations, and cutting-edge technologies, we address critical gaps in diagnostics, preventive care, and population health—while upholding the highest standards of quality, ethics, and data integrity.
We take pride in supporting healthcare institutions, clinicians, and patients with a growing portfolio of genomic innovations that align with the Kingdom’s national priorities and the aspirations of Vision 2030. We also believe that sustained impact requires strategic collaboration—with government stakeholders, academic institutions, and the global scientific community.
At Novo Genomics, we are driven by purpose, powered by science, and inspired by the opportunity to shape the future of healthcare in the region and beyond. Thank you for your continued trust.
